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Abstract
Introduction: The search for new compounds with cardioprotective activity amongst the 3-(2,2,2-trimethylhydrazini- 
um) propionate derivatives looks promising.
Research objectives: to study cardioprotective effects of the 3-(2,2,2-trimethylhydrazinium) propionate derivatives.
Methods: The cardioprotective effect of the derivatives (nicotinate, 5-hydroxynicotinate) of 3-(2,2,2-trimethylhydrazini- 
um) propionate) and reference medicine meldonium in the case of doxorubicin (DOX) (20 mg/kg, intraperitoneally for 
48 hours) cardiomyopathy was evaluated by the results of a functional test with high-frequency stimulation (480 bpm).
To provide integral validation for the development of the simulated pathological processes, biochemical and morpho­
logical studies of the heart were carried out. For a biochemical evaluation of myocardial damage in the homogenisate, 
the isoenzyme creatinine kinase MB (CK-MB) and lactate dehydrogenase (LDH) were determined.
Results: The derivatives nicotinate and 5-hydroxynicotinate of 3-(2,2,2-trimethylhydrazinium) propionate) exert a 
cardioprotective effect on a doxorubicin pathology model, which is expressed in a decreased coefficient of diastolic 
dysfunction (StTTI) to the level of 5.8±0.1 ru and 4.6±0.2 ru in comparison with that in the control group 8.3±0.1 ru and 
reference medicine meldonium 6.5±0.1 ru, respectively.
The cardioprotective effect was confirmed by decreased levels of markers of damage to CK-MB and LDH and a de­
creased diameter of cardiomyocytes compared to those in the control group.
Conclusion: The derivatives of 3-(2,2,2-trimethylhydrazinium) propionate (nicotinate, 5-hydroxynicotinate) 
3-(2,2,2-trimethylhydrazinium) propionate reduce diastolic dysfunction and irreversible damage to cardiomyocytes in 
case of doxorubicin-associated cardiomyopathy.
Keywords
nicotinate of 3-(2,2,2-trimethylhydrazinium) propionate, 5-hydroxynicotinate of 3-(2,2,2-trimethylhydrazinium) propi­
onate, meldonium, doxorubicin cardiopathy, isolated rat heart.
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Introduction
Most anthracycline drugs, in particular DOX, are still wi­
dely used chemotherapeutic agents (Shuykova et al. 2012, 
Xiong et al. 2018). However, the use of anthracyclines is 
limited due to the chances of developing severe cardio­
myopathy, which is accompanied by progressive systolic 
dysfunction of the left ventricle (LV) leading to irreversi­
ble congestive heart failure (Cappetta et al. 2017).
Modern concepts consider several possible mechanis­
ms underlying the cardiotoxicity of doxorubicin: oxida­
tive and nitrosative stresses, dysregulation of intracellular 
calcium level, pathological changes in the performance 
of mitochondria, selective inhibition of expression of car- 
diomyocyte-specific genes, which ultimately leads to the 
activation of cell death mechanisms (Sterba et al. 2013, 
Renu et al. 2018, Mantawy et al. 2018).
DOX-induced cardiotoxicity can be overcome in va­
rious ways. However, substances with cardiotropic effects 
are looked for amongst various classes of chemical and 
pharmacological groups (Popelova et al. 2008, Zhao et al. 
2018, Pecoraro et al. 2018, Gu et al. 2017).
This is the reason that the purpose of this study was 
defined as the study of the cardioprotective effects of new 
3-(2,2,2-trimethylhydrazinium) propionate derivatives.
Materials and methods
The object of the study was two new derivatives of 
3-(2,2,2-trimethylhydrazinium) propionate, (the laborato­
ry codes of the development institution are CTK-733 and 
CTK-735; the structural formulae of the substances are 
shown in Fig. 1.
The experiments were performed on 50 mature Wistar 
rats of both sexes weighing 220±20 g. All activities with 
the animals were carried out in compliance with “The 
European Convention for the Protection of Vertebrate 
Animals used for Experiment or Other Scientific Purpo­
ses” (Derective2010/63/EU). All the experiments were 
approved by the local Ethics Committee (Minutes No. 
9-2016 of 17 March 2017).
The cardioprotective activity of substances CTK-733 
(189 mg/kg/day) and CTK-735 (199.1 mg/kg/day) was stu-
nicotinate-3 -(2,2,2- 5-hydroxynicotinate-3 -(2,2,2-
trimetliylhydrazinium)poTassium Trimethylhydrazinmm)potassium
propionate propionate
Figure 1. Chemical structures of 3-(2,2,2-trimethylhydrazini- 
um) propionate derivatives.
died in the model of DOX-induced cardiotoxicity (20 mg/ 
kg, intraperitoneally for 48 hours) by imposing on the heart 
a submaximal stimulation rate (480 beats per minute) and 
hypercalcium perfusion (5 mmol/l) in an isolated Langen- 
dorff rat heart (Danilenko and Pokrovskii 2014). Reference 
medicine meldonium (Mildronata manufactured by GRIN- 
DEX, Latvia) was administered at a dose of 90 mg/kg/day.
Biochemical markers of damage were assessed by the 
conventional methods.
The micropreparations study, photorecording and 
morphometry were carried out using a Leica DM 4000B 
microscope equipped with a video recording system and 
software for image archiving and analysing -  Leica Ap­
plication Suite Version 3.8.0. The diameters of the cardio- 
myocytes were measured in strictly longitudinal sections.
Results and discussion
DOX-induced cardiotoxicity was characterised by a de­
creased myocardial contractility. The principal difference 
in the area under the curve of the end-diastolic pressure 
build-up when imposing a high rhythm of contractions at 
480 bpm for 11 seconds with a background of increased 
Ca2+ concentration up to 5 mmol in the perfusate in the 
intact group and with a background of DOX in the con­
trol group, logically led to the necessity of introducing the 
StTTI factor, which is quite indicative and informative and 
which can be used for screening innovative molecules.
Conducting a functional test with high-frequency sti­
mulation revealed the development of “the diastole de­
fect” (Fig. 2b) and StTTI increased to 8.3±0.3 ru when com­
pared with the intact animals, 1.4±0.1 ru, i.e. an eight-fold 
increase (Fig. 2a).
The tested substances CTK-733 (189 mg/kg/day) and 
CTK-735 (199.1 mg/kg/day), reference medicine meldo- 
nium (90 mg/kg/day), prevented the reduction of contrac­
tility when sampling at a high-frequency stimulation StTTI 
to the level of 5.8±0.1 ru and 4.6±0.2 ru, respectively. The 
StTTI value of meldonium amounted to 6.5±0.1 ru.
The cardioprotective effect of the derivatives was con­
firmed by decreased levels of markers of damage CK-MB 
and LDH, as well as a decreased diameter of cardiomyo- 
cytes (Table 1).
Thus, the derivatives of 3-(2,2,2-trimethylhydrazinium) 
propionate -  CTK-733 (189 mg/kg/day) and CTK-735 
(199.1 mg/kg/day) -  exerted a cardioprotective effect in a 
model of doxorubicin myocardiopathy, which on the basis 
of functional, biochemical and morphological parameters, 
exceeded the reference medicine meldonium (90 mg/kg).
The comparative dynamic evaluation of the parameters 
of the contractile activity of the hearts of the groups under 
study made it possible to establish that the use of both 
CTK-733 (189 mg/kg/day) and CTK-735 (199.1 mg/kg/ 
day) promoted the stability of the contractile apparatus 
of the cardiac muscle, which convincingly demonstrates 
their pronounced cardioprotective effect. The ability of 
CTK-733 (189 mg/kg/day) and CTK-735 (199.1 mg/kg/
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Figure 2. Loading test with submaximal electrostimulation of the isolated Langendorf rat heart. Key: The dynamics of pressure in 
the left ventricle (mm Hg) with the cardiac stimulation (480 beats per minute) for 11 seconds. Concentrations of Ca2+ in the perfusate 
5 mmol/l. Intact group (a). Doxorubicin (20 mg/kg) once per 48 hours (b). From top to bottom: scale 1 -  left ventricular pressure 
(LVP in mm Hg); scale 2 -  cardiac pacing (480 beats per minute for 11 seconds); scale 3 -  the rate of change of the LDVP (+dP/ 
dt , -dP/dt , mm Hg/sec)max’ max
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Table 1. Effect of CTK-733 (189 mg/kg/day), CTK-735 (199.1 mg/kg/day) and meldonium (90 mg/kg/day) on functional, biochem­
ical and morphological indices in case of DOX-induced cardiotoxicity (M+m; n = 10)
Group St ITT (ru) CK-MB (IU/L) LDH
(IU/L)
diameter of cardiomyocytes 
(Pm)
Intact animals 1.4+0.1* 98.0+11.8* 263.0+24.9* 8.1+0.3*
DOX (20 mg/kg) control 8.3+0.3** 740.0+13.6** 1583.0+30.6** 17.3+0.4**
DOX (20 mg/kg) + СТК-733 
(189 mg/kg/day)
5.8+0.1* 592.1+9.3* 1347+23.5* 13.9+0.1*
DOX (20 mg/kg) + СТК-735 
(199.1 mg/kg/day)
4.6+0.2* 464.3+10.1* 988.7+25.8* 10.5+0.2*
DOX (20 mg/kg) + meldonium 
(90 mg/kg/day)
6.5+0.3* 618.4+7.2* 1311.8+19.7* 14.8+0.3*
Key: The coefficient of diastolic dysfunction StlTT (ru), creatine kinase CK-MB (IU/L), lactate LDH (IU/L), ** -  р<0.05 compared 
to the group of intact animals; * -  р<0.05 compared to the control.
day) to prevent damage to cell membranes was also asses­
sed by the positive dynamics of changes in the activity of 
CK-MB and LDH and the diameter of cardiomyocytes.
Anthracycline cardiomyopathy is a multifactorial pro­
cess that leads to apoptosis and death of cardiomyocytes. 
Disturbance of metabolism is an important cause for the 
development of DOX cardiomyopathy (Huang et al. 2018, 
McLaughlin et al. 2017). The heart requires a large amount 
of energy to provide contractility. In the isolated models of 
cardiomyocytes, DOX was shown to reduce concentrations 
of intracellular adenosine triphosphate (ATP) and phospho- 
creatine (PK) by more than 50% within 24 hours (Menna 
and Salvatorelli 2017). More than 90% of ATP used by car- 
diomyocytes is produced in the process of mitochondrial 
respiration. The prolonged influence of doxorubicin on iso­
lated myocardial mitochondria leads to a rapid disruption 
of oxidative mitochondrial processes (Kankeu et al. 2017). 
There are several practical pharmacological strategies for 
preventing the development of left ventricular (LV) dys­
function and cardiac failure (CF) caused by anthracyclines. 
They are ACE inhibitors, ARB inhibitors and BB, as well 
as using dexrazoxane as a cardioprotector (ESC 2017). Ho­
wever, despite numerous clinical and experimental studies, 
the approaches used for cardioprotection of toxic lesions 
with anthracyclines are not without shortcomings and re­
quire new promising pharmacological approaches. When 
treating with doxorubicin, an increase in the level of fatty 
acids is observed in the serum. Doxorubicin inhibits the 
oxidation of palmitate, a long-chain fatty acid. A possible 
mechanism is supposed to be damage to Carnitine palmitoil 
transferase 1 and/or depletion of L-carnitine stocks. A redu­
ced rate of glycolysis may be due to the effect of DOX on 
maintaining the level of glucose and/or on the cells’ ability 
to stimulate its production. Meldonium, by suppressing the 
synthesis and re-absorption of carnitine, reduces the trans­
port of long-chain fatty acids in the mitochondrion and 
prevents damage to mitochondrial membranes due to the 
accumulation of fatty acid metabolites in them. As a result 
of limited transport and oxidation of fatty acids, there ap­
pears to be an alternative way for energy production in the 
mitochondria by oxidation of glucose. Besides, meldonium 
activates the two most important enzymes of aerobic gly­
colysis -  hexokinase and pyruvate dehydrogenase, which 
involve the pyruvate formed from sugars into the Krebs cy­
cle, preventing the formation of lactate. Under the influen­
ce of meldonium, the activity of these enzymes increases 
and their biosynthesis is induced, resulting in preventing 
the development of acidosis, which is harmful to cells. The 
metabolic pathway in doxorubicin cardiomyopathy is also 
discussed (Schaupp et al. 2015). It is well known that the 
introduction of new functional groups into a drug molecu­
le leads to a change in its pharmacological effect, which 
can show in an expanded spectrum of its therapeutic effect, 
improved or weakened therapeutic effect and the appearan­
ce of new properties. In order to analyse the possibility of 
enhancing the cardioprotective effects detected in meldoni- 
um, essentially different functional groups with respect to 
the chemical structure of a basic molecule were introduced 
into a molecule of 3-(2,2,2- trimethylhydrazinium) propi­
onate, namely the residue of substituted and unsubstituted 
nicotinic and 5-hydroxynicotinic acid.
Nicotinic acid was chosen as an object to be introduced 
into the base molecule for a reason. It exerts an unusually 
wide range of effects for small (10-200 mg/day) and large 
(over 1000 mg/day) doses and is already widely used in 
practical medicine. Moreover, a pharmacological compo­
sition containing a hydroxyl group that enhances the anti­
oxidant properties of the molecule exerted the maximum 
cardioprotective effect in case of doxorubicin-associated 
cardiomyopathy. The reason for this is that one of the al­
leged causes of DOX-induced cardiotoxicity is related to 
the effect on iron metabolism: anthracyclines bind to Fe2+ 
ions, which leads to the formation of a hydroxyl radical 
and promotes the release of Fe2+ ions from ferritin, exa­
cerbating oxidative stress even further.
Therefore, if in the cell cytoplasma, there arise the con­
ditions for chelation or oxidation of ferrous (Fe2+) ions 
into the catalytically inactive state of Fe3+ ions, leading 
to a decrease in the effective concentration of hydroxyl 
radicals, this will create the conditions for achieving mi­
cromolar concentrations of ROS in the cytoplasm of cells. 
The substances possessing an antioxidant effect play an 
important role in regulating free-radical mechanisms. As 
an example of such a scheme, it can be assumed that CTK-
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733 and CTK-735 possess the property of the chelator 
Fe2+ and the oxidant Fe2+ in Fe3+. In addition, control over 
the concentration of Fe2+ can be important in regulating 
free-radical reactions: lipid peroxidation, inactivation of 
proteins and nucleic acids. Derivatives of 3-(2,2,2-trime- 
thylhydrazine) propionate, having the chelating property 
of Fe2+ and oxidising property of Fe2+ to Fe3+, can inhibit 
free radical oxidation catalysis and thereby inhibit free ra­
dical oxidation, which in turn reduces cardiotoxicity from 
DOX (Montaigne et al. 2012).
Thus, meldonium and its derivatives CTK-733 and 
CTK-735 demonstrated high efficacy and safety when
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